Xylong (Spray, Drops) Instructions for Use
ATC Code
R01AB06 (Xylometazoline in combination with other drugs)
Active Substances
Dexpanthenol (Rec.INN registered by WHO)
Xylometazoline (Rec.INN registered by WHO)
Clinical-Pharmacological Group
Vasoconstrictor drug for topical use in ENT practice
Pharmacotherapeutic Group
Drugs for the treatment of nasal diseases; decongestants and other drugs for topical use; sympathomimetics, combinations without corticosteroids
Pharmacological Action
A combined medicinal product for topical use.
Xylometazoline belongs to the group of local vasoconstrictors (decongestants) with alpha-adrenomimetic activity. It causes constriction of the blood vessels of the nasal mucosa, restores the patency of the nasal passages, and facilitates nasal breathing. The drug’s effect usually begins within a few minutes after application and lasts up to 10 hours.
Dexpanthenol is a B vitamin, a derivative of pantothenic acid. Dexpanthenol is converted in the body into pantothenic acid, which is a component of coenzyme A and is involved in acetylation processes, carbohydrate and fat metabolism, and in the synthesis of acetylcholine, corticosteroids, and porphyrins. It stimulates the regeneration of the skin and mucous membranes, normalizes cellular metabolism, accelerates mitosis, and increases the strength of collagen fibers. It has a regenerating, metabolic, and weak anti-inflammatory effect.
Pharmacokinetics
Xylometazoline, when applied topically, is practically not absorbed; plasma concentrations are so low that they cannot be determined by modern analytical methods.
Dexpanthenol, when applied topically, is rapidly absorbed by the skin and converted into pantothenic acid, which binds to plasma proteins (mainly to beta-globulin and albumin). Its concentration in the blood is 0.5-1 mg/l, in blood serum – 100 µg/l. Pantothenic acid is not metabolized in the body (except for incorporation into CoA) and is excreted unchanged.
Indications
Acute respiratory diseases with symptoms of rhinitis; acute allergic rhinitis; vasomotor rhinitis; sinusitis; otitis media (as part of combination therapy to reduce swelling of the nasopharyngeal mucosa); to facilitate rhinoscopy; to restore impaired nasal breathing after surgical interventions in the nasal cavity.
ICD codes
| ICD-10 code | Indication |
| H66 | Suppurative and unspecified otitis media |
| J00 | Acute nasopharyngitis (common cold) |
| J01 | Acute sinusitis |
| J06.9 | Acute upper respiratory infection, unspecified |
| J30.0 | Vasomotor rhinitis |
| J30.1 | Allergic rhinitis due to pollen |
| J30.3 | Other allergic rhinitis (perennial allergic rhinitis) |
| J32 | Chronic sinusitis |
| Z51.4 | Preparatory procedures for subsequent treatment or examination, not elsewhere classified |
| ICD-11 code | Indication |
| AA9Z | Unspecified suppurative otitis media |
| CA00 | Acute nasopharyngitis |
| CA01 | Acute rhinosinusitis |
| CA07.0 | Acute upper respiratory tract infection of unspecified site |
| CA08.00 | Allergic rhinitis due to pollen |
| CA08.03 | Other allergic rhinitis |
| CA08.3 | Vasomotor rhinitis |
| CA0A.Z | Chronic rhinosinusitis, unspecified |
| QB9A | Preparatory procedures for subsequent treatment |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
For intranasal use only. Administer the spray or drops with the head in an upright position.
For adults and children over 6 years of age, administer one spray or 2-3 drops into each nostril.
Apply the medication three to four times daily, as needed for nasal congestion.
The maximum duration of continuous treatment is 5 days. Do not exceed this duration.
For children aged 2 to 6 years, use only the pediatric formulation and consult a physician for appropriate dosage.
This product is contraindicated for children under 2 years of age.
Before administration, clear the nasal passages by gently blowing the nose.
Avoid frequent or prolonged use beyond the recommended duration to prevent rebound congestion.
If symptoms persist after 5 days, discontinue use and seek medical advice.
Adverse Reactions
With frequent and/or prolonged use: irritation and/or dryness of the nasopharyngeal mucosa, burning, tingling, sneezing, hypersecretion, allergic reactions, swelling of the nasal mucosa, vomiting, headache, dry rhinitis, palpitations, increased blood pressure, insomnia, visual disturbances, depression (with long-term use of high doses).
Contraindications
Arterial hypertension; tachycardia; severe atherosclerosis; atrophic rhinitis; hyperthyroidism; porphyria; prostatic hyperplasia; glaucoma; surgical interventions on the meninges (in history); children under 2 years of age; children under 6 years of age (for dosage forms intended for older children and adults); simultaneous therapy with MAO inhibitors and tricyclic antidepressants; hypersensitivity to the components of the medicinal product.
With caution
Diabetes mellitus, pheochromocytoma.
Use in Pregnancy and Lactation
Use during pregnancy and lactation (breastfeeding) is not recommended.
Pediatric Use
Contraindicated in children under 6 years of age.
Special Precautions
It is necessary to clean the nasal passages before use.
Should not be used for more than 5 days.
Influence on the ability to drive vehicles and mechanisms
During the period of use, precautions should be observed, or driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions should be avoided.
Drug Interactions
With simultaneous use of MAO inhibitors and tricyclic antidepressants, an increase in systemic action is possible.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Nasal drops 1 mg+50 mg/1 ml: dropper bottle 15 ml
Marketing Authorization Holder
Lekko, CJS (Russia)
Dosage Form
| Xylong | Nasal drops 1 mg+50 mg/1 ml: dropper bottle 15 ml |
Dosage Form, Packaging, and Composition
Nasal drops in the form of a transparent, colorless liquid.
| 1 ml | |
| Xylometazoline hydrochloride | 1 mg |
| Dexpanthenol | 50 mg |
Excipients : sodium citrate dihydrate – 5.09 mg, sodium chloride – 2.5 mg, hypromellose – 1 mg, benzalkonium chloride – 0.15 mg, citric acid monohydrate – to pH 4.4 (3.5 mg), purified water – up to 1 ml.
15 ml – polymer dropper bottles (1) – cardboard packs.
Metered-dose nasal spray 0.1 mg+5 mg/1 dose: bottle 15 ml (100 doses)
Marketing Authorization Holder
Pharmstandard-Lexredstva OJSC (Russia)
Dosage Form
| Xylong | Metered-dose nasal spray 0.1 mg+5 mg/1 dose: bottle 15 ml (100 doses) |
Dosage Form, Packaging, and Composition
Metered-dose nasal spray in the form of a transparent, colorless liquid.
| 1 dose | |
| Xylometazoline hydrochloride | 0.1 mg |
| Dexpanthenol | 5 mg |
Excipients : sodium citrate dihydrate – 0.509 mg, sodium chloride – 0.25 mg, hypromellose – 0.1 mg, benzalkonium chloride – 0.015 mg, citric acid monohydrate – 0.35 mg, purified water – up to 100 µl.
15 ml (100 doses) – polymer bottles (1) with a metering pump complete with a spray nozzle – cardboard packs.
Metered-dose nasal spray 0.05 mg+5 mg/1 dose: bottle 15 ml (100 doses)
Marketing Authorization Holder
Pharmstandard-Lexredstva OJSC (Russia)
Dosage Form
| Xylong Kids | Metered-dose nasal spray 0.05 mg+5 mg/1 dose: bottle 15 ml (100 doses) |
Dosage Form, Packaging, and Composition
Metered-dose nasal spray in the form of a transparent, colorless liquid.
| 1 dose | |
| Xylometazoline hydrochloride | 0.05 mg |
| Dexpanthenol | 5 mg |
Excipients : sodium citrate dihydrate – 0.509 mg, sodium chloride – 0.25 mg, hypromellose – 0.1 mg, benzalkonium chloride – 0.015 mg, citric acid monohydrate – 0.35 mg, purified water – up to 100 µl.
15 ml (100 doses) – polymer bottles (1) with a metering pump complete with a spray nozzle – cardboard packs.
No-spa pills 40mg, 64pcs
Cavinton Comfort, dispersible pills 10mg 90pcs
Cortexin, 10mg, 5ml, 10pcs
Mildronate capsules 500mg, 90pcs
Belosalic, ointment, 30g
Ingavirin capsules 90mg, 10pcs
Actovegin pills 200mg, 50pcs
Cerebrolysin, solution for injection 2ml ampoules 10pcs
Arbidol, capsules 100mg, 40pcs
Nootropil pills 800mg, 30pcs
Picamilon pills 50mg, 60pcs
Belosalic, lotion solution for external use spray 100ml
Kagocel pills 12mg, 30pcs
OKI, sachets 80mg 2g, 12pcs
Phenibut-Vertex pills 250mg, 20pcs
Daivobet, ointment, 30g
Noopept, pills 10mg, 50pcs 